Diabetes is a metabolic disorder where the pancreas produces little or no insulin (Type I) OR cells do not respond appropriately to insulin that is produced (Type II). It is estimated that the global prevalence of diabetes is estimated at over 371 million people, a number predicted to rise significantly by 2030. Diabetes, although manageable, can lead to a number of complications, many of which can be fatal. It is estimated that 4.6 million people aged between 20-79 died from diabetes in 2011.
Since Type 1 diabetes is an autoimmune disorder, there is a plausible role for a vaccine which may prevent or slow the damage being caused to the beta-cells in the pancreas. Consequently several different approaches have been explored involving immunomodulatory candidates. The most advanced clinical candidate has been Diamyd's, GAD (recombinant human glutamic acid decarboxylase protein) based therapy which is currently in Phase II clinical testing. MarketVIEW: Diabetes Vaccines is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of diabetes vaccines across major Western markets until 2030. The model contains value ($ m) and volume (mio doses) predictions along with timeframe, pricing and penetration estimates for all adult/pediatric risk groups depending on stage of diabetes/risk profile. The product also includes an up-to-date review of disease epidemiology and competitor R&D pipeline activity.